<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03289949</url>
  </required_header>
  <id_info>
    <org_study_id>2016-004000-61</org_study_id>
    <nct_id>NCT03289949</nct_id>
  </id_info>
  <brief_title>The Neurobiological Effect of 5-HT2AR Modulation</brief_title>
  <official_title>The Neurobiological Effect of 5-HT2AR Modulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gitte Moos Knudsen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to investigate neurobiological effects of serotonin 2A receptor&#xD;
      modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an&#xD;
      antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography&#xD;
      (PET) will be used as neuroimaging tools.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psilocin/ketanserin blood concentrations and 5-HT2A receptor occupancy (i.e., binding potential).</measure>
    <time_frame>Change in Cimbi-36 binding potential from baseline PET to intervention PET 1 and PET 2 scans (same day for psilocybin, and two consecutive days for ketanserin).</time_frame>
    <description>The investigators aim to model relations psilocin/ketanserin blood drug concentrations and receptor occupancy, using C11-Cimbi-36 PET imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of psilocybin on Cimbi-36 binding potential at baseline and at one and twelve weeks</measure>
    <time_frame>Change in Cimbi-36 binding potential from baseline to one week post psilocybin (and potentially also at 12 weeks after psilocybin).</time_frame>
    <description>Cimbi-36 PET scan binding potential at baseline and at one-week post psilocybin, and potentially also at 12 weeks post psilocybin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of psilocybin and ketanserin on brain function assessed with fMRI and PET</measure>
    <time_frame>Changes in functional connectivity (fMRI) from Baseline MR to intervention MR scans for ketanserin (one or three weeks after baseline MR) and psilocybin (one or three weeks after baseline)</time_frame>
    <description>Correlations between blood levels of ketanserin and psilocin and the estimated associated receptor occupancy with functional MRI neuroimaging data, including resting state networks. Changes in synaptic density will be assessed with 11C-UCB-J PET scans before and 1 week after psilocybin intervention.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Basic Science</condition>
  <arm_group>
    <arm_group_label>Project 1: Occupancy of psilocybin/ketanserin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After baseline MRI &amp; 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Project 2: Long term effects of psilocybin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After baseline MRI &amp; CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Project 3: Functional connectivity and synaptic plasticity</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybine</intervention_name>
    <description>Oral dose of psilocybine.</description>
    <arm_group_label>Project 1: Occupancy of psilocybin/ketanserin</arm_group_label>
    <arm_group_label>Project 2: Long term effects of psilocybin</arm_group_label>
    <arm_group_label>Project 3: Functional connectivity and synaptic plasticity</arm_group_label>
    <other_name>Psilocybin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketanserin</intervention_name>
    <description>Oral dose of ketanserin.</description>
    <arm_group_label>Project 1: Occupancy of psilocybin/ketanserin</arm_group_label>
    <arm_group_label>Project 3: Functional connectivity and synaptic plasticity</arm_group_label>
    <other_name>Ketensin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) Healthy individuals above 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10&#xD;
             diagnostic classifications) or in first-degree relatives.&#xD;
&#xD;
          2. Previous or present neurological condition/disease, significant somatic&#xD;
             condition/disease or intake of drugs suspected to influence test results.&#xD;
&#xD;
          3. Non-fluent Danish language skills.&#xD;
&#xD;
          4. Vision or hearing impairment.&#xD;
&#xD;
          5. Previous or present learning disability.&#xD;
&#xD;
          6. Pregnancy.&#xD;
&#xD;
          7. Breastfeeding.&#xD;
&#xD;
          8. Contraindications in regard to MRI scanning.&#xD;
&#xD;
          9. Alcohol or drug abuse.&#xD;
&#xD;
         10. Allergy to test drugs.&#xD;
&#xD;
         11. Participation in studies in which participant has received more than 10 mSv of&#xD;
             radiation or other significant exposure to radiation.&#xD;
&#xD;
         12. Abnormal ECG or intake of QT prolonging medication.&#xD;
&#xD;
         13. Previous significant side-effects in regard to hallucinogenic drugs.&#xD;
&#xD;
         14. Use of hallucinogenic drugs 6 months previous to inclusion.&#xD;
&#xD;
         15. Blood donation 3 months before and after project participation&#xD;
&#xD;
         16. Bodyweight under 50 kg.&#xD;
&#xD;
         17. Plasma ferritin levels outside normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gitte M Knudsen, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Neurobiology Research Unit, Rigshospitalet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gitte M Knudsen, Professor</last_name>
    <phone>+45 35456720</phone>
    <email>gmk@nru.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin K Madsen, MD</last_name>
    <phone>+45 35456708</phone>
    <email>martin@nru.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurobiology Research Unit, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitte M Knudsen, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Patrick M Fisher, PhD</last_name>
      <phone>+4535456714</phone>
      <email>patrick.fisher@nru.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2017</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Gitte Moos Knudsen</investigator_full_name>
    <investigator_title>Professor, DMsc, MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketanserin</mesh_term>
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Via database of Center for Integrated Molecular Brain Imaging (Knudsen et al 2016, NeuroImage) data will be available for neuroscience research community contingent on approval by scientific board.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

